Cerevance Publishes CVN293 in ACS Medicinal Chemistry Letters
BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, today announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.
- BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system diseases, today announced that the peer-reviewed journal, ACS Medicinal Chemistry Letters, has published the manuscript titled “Discovery of CVN293, a Brain Permeable KCNK13 (THIK-1) Inhibitor Suitable for Clinical Assessment”.
- CVN293, currently in a Phase 1 study in healthy volunteers, targets the NETSseq-identified, potassium (K+) ion channel, KCNK13, which is specifically expressed in human microglia.
- Elevated KCNK13 levels have been observed in post-mortem human brain tissue from individuals with Alzheimer’s disease and other neurodegenerative conditions.
- “We are delighted to publish the discovery of CVN293 as we anticipate its ability to selectively suppress neuroinflammation while mitigating impacts on the peripheral immune system,” said Mark Carlton, Ph.D., chief scientific officer for Cerevance.